Surgery Partners price target lowered to $34 from $35 at Macquarie
The Fly

Surgery Partners price target lowered to $34 from $35 at Macquarie

Macquarie analyst Tao Qiu lowered the firm’s price target on Surgery Partners (SGRY) to $34 from $35 and keeps an Outperform rating on the shares. The firm notes the company reported an in-line quarter and reaffirmed revenue/adjusted EBITDA guidance. Free cash flow outlook tempered due to elevated transaction spending and others, Macquarie says, adding that case volume led organic revenue growth, while rate was affected by mix shift but remains strong year-to-date.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App